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169 A new tool to improve inhalation
J. Wikstro¨m1. 1KTH, Computer Science and Communication, Stockholm, Sweden
Objectives: Inhalation of medicine is a common way to treat CF and is very
effective when performed correctly. In practice however, inhalation monitored by a
physiotherapist is much more effective than inhalation at home due to:
• Lack of technique
• Lack of motivation
• Presence of distractions
The goal of this project is to emulate a physiotherapy inhalation session to increase
the amount of medicine delivered to the lungs every day. The secondary goal is to
provide a tool for physiotherapy research.
Methods: By connecting a spirometer to a nebulizer, a software I have developed
can guide the patient to a better inhalation. The air ﬂow and volume measurements
can also be logged and saved for later analysis by a physiotherapist. The software
can be modiﬁed into a computer game for children, a youtube viewer for adults
or anything in between. It can also be extended for inhalation research with new
inhalation techniques.
Results: The software has only been tested on me so far and in the the last year I
have had to use signiﬁcantly less IV treatments. If this effect is due to the inhalation
software remains to be shown in further studies. The software has increased quality
of life since the the time spent on inhalation has become more worthwhile and
enjoyable.
Conclusion: This software is an exciting new way to improve inhalation and an
exciting new tool for inhalation researchers. The software has not been tested on
enough patients to prove the improvement in inhalation, but the initial reactions
from the CF community has been highly positive.
170 The King’s experience of Bronchitol®. One UK centre’s results of
Bronchitol® initiation
E. Scott1, C. Reilly1, C. Elston1, F. Perrin1, K. Lee1. 1King’s College Hospital,
London, United Kingdom
Objectives: To assess in a clinical setting, the tolerability and effect of Bronchitol®
(mannitol) in adult patients with CF.
Method: Retrospective study of patients who had completed a Bronchitol® Initia-
tion Dose Assessment (BIDA) between April 2013 and November 2013. Tolerability
was assessed by the percentage (%) of patients passing the BIDA and % continuing
treatment for 2 months. FEV1 at assessment and at 2 months were compared. For
those who discontinued Bronchitol®, a reason for stopping was recorded.
Results: 27 patients were identiﬁed, mean age of 24 years, 52% female, mean
FEV1 1.3 l, mean FEV1 37% predicted. 24/27 (89%) patients passed the BIDA,
of whom 18 (75%) continued the use of Bronchitol® for 2 months. Of these, 14
also used Pulmozyme® as a mucolytic but were initiated on Bronchitol® due to
deterioration in condition.
Of the 6 (25%) patients who stopped using Bronchitol® before the 2 month stage,
3 (12.5%) stopped due to increased coughing, 2 (8%) could not ﬁt the treatment
regime into their daily routine and 1 (4%) underwent lung transplantation.
There was a signiﬁcant increase in mean (sd) FEV1 (L) (D0.124 (0.188) p = 0.014)
and FEV1%pred (D4.4 (5.6) p = 0.004) in those who continued to use Bronchitol®.
Conclusion: In our patient cohort Bronchitol® was well tolerated. In those who
continued to use Bronchitol® for 2 months, an improvement in lung function was
observed.
171 The patients’ view of nebulised drugs: knowledge, adherence,
and difﬁculties
K. Miles1, S. Lenaghan1, L. Blanch1, S. Doe1, S. Bourke1, M. Caraher1,
A. Anderson1. 1Royal Victoria Inﬁrmary, Newcastle Upon Tyne, United Kingdom
Background: An increasing number of inhaled antibiotics and mucolytics are
available for treating patients with cystic ﬁbrosis. However these are time consuming
to take and can provoke adverse effects such as cough and chest tightness. Patients
constantly make judgements in balancing the beneﬁt of treatments against the
burden imposed.
Method: We undertook a structured interview of 100 patients (55 men; age
17−67 years, FEV1 16–124% predicted) to determine their perspective of nebulised
therapies.
Results: 47% were on one nebulised drug and 53% on several. Most knew their
correct prescription (tobramycin 100%, colistin 98%, DNase 92%, hypertonic saline
(HTS) 50%) and the purpose of the drug (tobramycin 82%, colistin 75%, DNase
87% and HTS 86%). Reported adherence in taking the drug ‘always/most of the
time’ varied (tobramycin 100%, colistin 77%, DNase 87%, HTS 72%). Patients
indicated a variety of reasons as to why they didn’t adhere to the prescribed regimen
including burden of treatments 15%, adverse effects 11%, lack of time 15%, atypical
situations (e.g. away on holidays) 12%, patient choice 17%, time taken for treatment
and cleaning equipment 16% and perception of beneﬁt 9%. Many patients had a
poor knowledge of care of nebuliser equipment. Treatment adherence did not appear
to be inﬂuenced by the nebuliser device.
Conclusion: This study shows that patients make judgements and exercise choices
about inhaled therapies and provides useful baseline data as a prelude to introducing
more formal ‘shared decision making’ practices (BMJ 2010; 341: 971−5) in
negotiating inhaled treatment options and decisions between patients and the CF
team.
172 Implementation of non-medical prescribing (NMP) within the
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A.C. Henry1, E. Forster1, N.J. Bell1, K. Bateman1. 1University Hospitals Bristol
NHS Foundation Trust, Bristol Adult Cystic Fibrosis Centre, Bristol, United
Kingdom
Objectives: To develop the role for non-medical prescribing (NMP) within the adult
CF team, providing patients with quicker and more efﬁcient access to medicines.
2 specialist physiotherapists in our CF centre qualiﬁed as NMP supplementary
prescribers. Our initial focus was to provide a physiotherapy led inhaled therapy
service.
Methods: A weekly inhaled therapy clinic run solely by the physiotherapists was
set up for ﬁrst dose trials of inhaled antibiotics and mucolytics. Protocols were
written for each drug and referral criteria set. All prescriptions were written by the
NMP physiotherapists. Patients were followed up at 1 and 3 months post trial to
assess tolerability and adherence. Patient and clinician feedback is being collected.
Results: Over 12 months, there were 275 trial referrals and corresponding ap-
pointments given to 121 patients. 14 patients did not attend. 10 different drugs
were trialled (n = 194 dry powder inhaled antibiotics, 16 nebulised antibiotics,
65 mucolytics). 6 patients failed the ﬁrst dose trial and 14 stopped the drug by
1 month review (not tolerated = 12, non-adherence = 2). Initial patient and clinician
satisfaction with the service is high.
Conclusion: The NMP inhaled therapy clinic has streamlined the process for
assessment of new inhaled medications enabling patients to start the drugs promptly.
Close follow up of tolerance and adherence to the medication prevents unnecessary
prescribing. The NMP role is now being developed to be implemented on the wards,
in clinic and in the community.
